Literature DB >> 32351769

All in Your Mind? New-Onset Dysphagia in a Previously Healthy Adolescent Child.

Jake Sequeira1, Douglas Willson1, Mark Marinello1.   

Abstract

A healthy 11-year-old male develops fear of choking secondary to progressive dysphagia that began in early childhood. No organic cause is found, and the patient is diagnosed with psychiatric oral aversion. The child is eventually transferred to a psychiatric facility, where a month later he has a possible aspiration event and is transferred to the local emergency room for respiratory distress before being admitted to the intensive care unit. Workup is notable for abnormal findings on brain imaging, and the diagnosis of Alexander's disease is made. This case highlights the importance of complete history-taking and examinations in pediatric patients. © Thieme Medical Publishers.

Entities:  

Keywords:  Alexander's disease; dysphagia; pediatric

Year:  2019        PMID: 32351769      PMCID: PMC7186026          DOI: 10.1055/s-0039-3401008

Source DB:  PubMed          Journal:  J Pediatr Intensive Care        ISSN: 2146-4626


  15 in total

1.  Ceftriaxone has a therapeutic role in Alexander disease.

Authors:  GianPietro Sechi; Manuela Matta; Giovanni A Deiana; Pietro Balbi; Tiziana Bachetti; Eleonora Di Zanni; Isabella Ceccherini; Alessandro Serra
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2009-11-27       Impact factor: 5.067

2.  Allogeneic bone marrow transplantation for Alexander's disease.

Authors:  M J Staba; S Goldman; F L Johnson; P R Huttenlocher
Journal:  Bone Marrow Transplant       Date:  1997-08       Impact factor: 5.483

3.  Alexander disease: diagnosis with MR imaging.

Authors:  M S van der Knaap; S Naidu; S N Breiter; S Blaser; H Stroink; S Springer; J C Begeer; R van Coster; P G Barth; N H Thomas; J Valk; J M Powers
Journal:  AJNR Am J Neuroradiol       Date:  2001-03       Impact factor: 3.825

4.  TRH therapy in a patient with juvenile Alexander disease.

Authors:  Keiko Ishigaki; Yasushi Ito; Yukio Sawaishi; Kayano Kodaira; Makoto Funatsuka; Nozomi Hattori; Kazutoshi Nakano; Kayoko Saito; Makiko Osawa
Journal:  Brain Dev       Date:  2006-06-13       Impact factor: 1.961

5.  Oligomers of mutant glial fibrillary acidic protein (GFAP) Inhibit the proteasome system in alexander disease astrocytes, and the small heat shock protein alphaB-crystallin reverses the inhibition.

Authors:  Guomei Tang; Ming D Perng; Sherwin Wilk; Roy Quinlan; James E Goldman
Journal:  J Biol Chem       Date:  2010-01-28       Impact factor: 5.157

6.  Alexander disease.

Authors:  Albee Messing; Michael Brenner; Mel B Feany; Maiken Nedergaard; James E Goldman
Journal:  J Neurosci       Date:  2012-04-11       Impact factor: 6.167

7.  Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease.

Authors:  Brinda Ravikumar; Coralie Vacher; Zdenek Berger; Janet E Davies; Shouqing Luo; Lourdes G Oroz; Francesco Scaravilli; Douglas F Easton; Rainer Duden; Cahir J O'Kane; David C Rubinsztein
Journal:  Nat Genet       Date:  2004-05-16       Impact factor: 38.330

8.  Autophagy induced by Alexander disease-mutant GFAP accumulation is regulated by p38/MAPK and mTOR signaling pathways.

Authors:  Guomei Tang; Zhenyu Yue; Zsolt Talloczy; Tracy Hagemann; Woosung Cho; Albee Messing; David L Sulzer; James E Goldman
Journal:  Hum Mol Genet       Date:  2008-02-14       Impact factor: 6.150

9.  Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function.

Authors:  Lynsey Meikle; Kristen Pollizzi; Anna Egnor; Ioannis Kramvis; Heidi Lane; Mustafa Sahin; David J Kwiatkowski
Journal:  J Neurosci       Date:  2008-05-21       Impact factor: 6.167

10.  GFAP mutations, age at onset, and clinical subtypes in Alexander disease.

Authors:  M Prust; J Wang; H Morizono; A Messing; M Brenner; E Gordon; T Hartka; A Sokohl; R Schiffmann; H Gordish-Dressman; R Albin; H Amartino; K Brockman; A Dinopoulos; M T Dotti; D Fain; R Fernandez; J Ferreira; J Fleming; D Gill; M Griebel; H Heilstedt; P Kaplan; D Lewis; M Nakagawa; R Pedersen; A Reddy; Y Sawaishi; M Schneider; E Sherr; Y Takiyama; K Wakabayashi; J R Gorospe; A Vanderver
Journal:  Neurology       Date:  2011-09-14       Impact factor: 11.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.